Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population.
We have recently found that serum levels of pigment epithelium-derived factor (PEDF), a glycoprotein with anti-oxidative and anti-inflammatory properties, are elevated in proportion to the accumulation of the number of the components of the metabolic syndrome. Since formation and accumulation of advanced glycation end products (AGEs) progress under the metabolic syndrome and that PEDF could inhibit the AGE-elicited tissue damage, it is conceivable that PEDF levels may be increased as a counter-system against AGEs in patients with the metabolic syndrome. However, correlation between circulating levels of AGEs and PEDF in humans remains to be elucidated. In this study, we investigated the relationship between serum AGE and PEDF levels in a general population and examined the effects of AGEs on PEDF gene expression in vitro. One hundred ninety-six Japanese subjects in a general population underwent a complete history and physical examination, determination of blood chemistries, including serum levels of AGEs and PEDF. In multiple regression analyses, creatinine, body mass index, triglycerides, AGEs and insulin were independently correlated with serum PEDF levels. AGEs dose-dependently increased PEDF gene expression in cultured adipocytes and liver cells. Our present study demonstrated first that circulating AGEs were one of the independent correlates of serum levels of PEDF. Adipose tissue and liver may be target organs for the AGE-induced PEDF overexpression in humans. Serum PEDF levels may be elevated in response to circulating AGEs as a counter-system against the AGE-elicited tissue damage.
Yamagishi
Sho-Ichi
S
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp
Matsui
Takanori
T
Adachi
Hisashi
H
Takeuchi
Masayoshi
M
D017667:Adipocytes / Q000378:metabolism; D000368:Aged; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D002478:Cells, Cultured; D005136:Eye Proteins / Q000097:blood* / Q000235:genetics; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007564:Japan; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000097:blood* / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism; D015843:Serpins / Q000097:blood* / Q000235:genetics; D012710:Serum Albumin, Bovine / Q000378:metabolism; D015854:Up-Regulation; D000099174:Pigment Epithelium-Derived Factor
D015415:Biomarkers; D005136:Eye Proteins; D017127:Glycation End Products, Advanced; D009414:Nerve Growth Factors; D012333:RNA, Messenger; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D015843:Serpins; D012710:Serum Albumin, Bovine; D000099174:Pigment Epithelium-Derived Factor; C081628:advanced glycation end products-bovine serum albumin